Paradigm Biopharmaceuticals (PAR) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PAR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Paradigm Biopharmaceuticals Issues 7 Million Convertible NotesJuly 7, 2025 | tipranks.comParadigm Biopharmaceuticals Limited (PBIGF) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.com‘After Typhoon’ Star & UFC Champion Zhang Weili Signs With ParadigmJuly 2, 2025 | msn.comTony Award Nominee John Douglas Thompson Signs With ParadigmJuly 1, 2025 | msn.comParadigm unlocks $40M loan – and sees a 75cps price not far awayJune 30, 2025 | msn.comParadigm Biopharmaceuticals Ltd Stock Price HistoryJune 26, 2025 | investing.comHealth Check: Paradigm makes scenic acquisitive detour, but it’s no strategic shiftJune 26, 2025 | msn.comParadigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-upJune 26, 2025 | msn.comChronic Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pacira BioSciences, Paradigm Biopharma, Tonix PharmaJune 20, 2025 | theglobeandmail.comParadigm activates first Aus site for osteoarthritis drug trialsJune 2, 2025 | msn.comPBIGF Paradigm Biopharmaceuticals LimitedMay 31, 2025 | seekingalpha.comThis stock could have something close to a cure for osteoarthritis. Don’t let it hide under your noseMay 20, 2025 | msn.comIHS Holding Limited: IHS Towers Agrees to Sell Rwanda Operations to Paradigm Tower VenturesMay 20, 2025 | finanznachrichten.deIHS Towers Agrees to Sell Rwanda Operations to Paradigm Tower VenturesMay 20, 2025 | finance.yahoo.comBiopharmaceuticals Market Forecast Report 2025-2034: Oncology Segment Captured 30.9% Share in 2024 Amid Surge in Targeted Cancer TherapiesMay 16, 2025 | finance.yahoo.comCressey & Company Announces Partnership with Leading Hospice Provider, Paradigm HealthMay 12, 2025 | finance.yahoo.comParadigm Signs ‘Virgin River’ & ‘The Good Doctor’ Director Felipe RodriguezMay 9, 2025 | msn.comIs Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?March 30, 2025 | finance.yahoo.comAdvanced Clinical chosen as CRO for Paradigm’s Phase III osteoarthritis trialFebruary 4, 2025 | msn.comParadigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy from Bell PotterFebruary 2, 2025 | markets.businessinsider.comParadigm for Parity® Names Former CEO Sandra Quince as President of Board of DirectorsJanuary 14, 2025 | finance.yahoo.comWhy these small cap ASX shares could deliver very big returns in 2025January 8, 2025 | fool.com.auWhy ANZ, Calix, Paradigm, and Platinum shares are tumbling todayDecember 9, 2024 | msn.comParadigm raises $16m for phase III trial of knee osteoarthritis treatmentDecember 9, 2024 | msn.comPhosCo runs hard on Tunisian phosphateNovember 29, 2024 | msn.comParadigm clear for phase 3 following US FDA reviewNovember 27, 2024 | msn.comWhy did this ASX biotech stock explode 52% higher on Monday?November 25, 2024 | msn.comParadigm Hires Sarah Shulman As VP Corporate CommunicationsNovember 22, 2024 | msn.comParadigm Biopharmaceuticals: Director’s Shareholding UpdateNovember 21, 2024 | markets.businessinsider.comParadigm Biopharmaceuticals Advances with Key ResolutionsNovember 19, 2024 | msn.comParadigm Biopharmaceuticals Targets Growth Amid Market ChallengesNovember 19, 2024 | markets.businessinsider.comParadigm Launches New Division The Sports GroupNovember 15, 2024 | msn.comParadigm Signs NFL’s Aaron Donald, Wife & Business Partner Erica DonaldNovember 12, 2024 | msn.comVincerx Pharma Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comPrilenia Therapeutics B.V.: Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 CongressNovember 6, 2024 | finanznachrichten.dePrilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 CongressNovember 6, 2024 | finance.yahoo.comHealth Check: Which biotech boards are at risk of a ‘second strike’?November 4, 2024 | msn.comParadigm Biopharma Advances Phase 3 Trials Amid Financial PrudenceOctober 31, 2024 | markets.businessinsider.comChina’s KKV is now open at JB’s Paradigm Mall — snacks, travel essentials & more from RM2.90October 25, 2024 | sg.style.yahoo.comParadigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics IncOctober 24, 2024 | finance.yahoo.comParadigm Biopharmaceuticals: Director Increases ShareholdingsOctober 23, 2024 | markets.businessinsider.comParadigm Biopharmaceuticals Plans New Securities IssuanceOctober 23, 2024 | markets.businessinsider.comBiotech Alert: Searches spiking for these stocks todayOctober 23, 2024 | markets.businessinsider.comBiocurious: Cracking the code on Paradigm Biopharmaceuticals’ valuation enigmaOctober 22, 2024 | msn.comHealth Check: Just the news we ‘kneed’ as Paradigm aims to kick-start US osteo trialOctober 21, 2024 | msn.comParadigm Biopharmaceuticals Boosts Confidence with Phase 3 PlansOctober 21, 2024 | markets.businessinsider.comInCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued DevelopmentSeptember 30, 2024 | finance.yahoo.comFDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?September 19, 2024 | msn.comParadigm steps closer to Phase 3 trial for knee arthritis treatment after FDA feedbackSeptember 18, 2024 | msn.comBreak it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA supportSeptember 18, 2024 | msn.com Get Paradigm Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter. Email Address PAR Media Mentions By Week PAR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PAR News Sentiment▼-0.271.01▲Average Medical News Sentiment PAR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PAR Articles This Week▼01▲PAR Articles Average Week Get Paradigm Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mitek Systems News Allot News Kopin News 3D Systems News Radcom News Lantronix News Markforged News AstroNova News Silicom News Identiv News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PAR) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
